Taysha (TSHA) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
Call participants Chief Executive Officer — Sean Nolan President and Head of R&D — Sukumar Nagendran Chief Financial Officer — Kamran Alam Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript Hayleigh Collins: A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Taysha Gene Therapies, Inc.'s Chief Executive Officer; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks. On today's call, we will be making forward-looking statements, including statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, to positively impact quality of life and alter the course of disease in the p
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies (TSHA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TSHA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "seMarketBeat
- Taysha Gene Therapies (TSHA) had its price target raised by Needham & Company LLC from $10.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]Yahoo! Finance
TSHA
Earnings
- 3/19/26 - Miss
TSHA
Sec Filings
- 3/19/26 - Form 10-K
- 3/19/26 - Form 8-K
- 2/27/26 - Form 144
- TSHA's page on the SEC website